KTR in US: GeneSys announces expansion plans in Genome Valley

WASHINGTON DC: IT and Industries Minister K.T. Rama Rao on Friday expressed delight over the expansion plans of GeneSys Biologics Pvt Ltd for Genome Valley which would not only contribute to the growth of Hyderabad's biotech sector but also facilitate their ongoing collaboration with US-based Civica Rx. He congratulated both companies as their efforts would contribute to addressing the Insulin affordability crisis and improve the lives of patients living with diabetes.

The Minister met GeneSys and Civica leadership, including Tom Damratoski, Sr. Vice President, Biologics, Civica, and Allan Coukell, Sr. Vice President, Public Policy, Civica & President, Civica Foundation, as well as Venkat Reddy Yelma, Director, and Roopesh Kondrella, Director, from GeneSys Biologics.

KTR expressed delight in learning that GeneSys, which had already invested approximately $50 million in Genome Valley, Hyderabad, had plans to invest an additional $50-60 million in setting up a new large-scale recombinant bulk manufacturing facility (from fermentation to purified bulk insulin) for its insulin analogues.

GeneSys, a science-based biopharmaceutical company headquartered in Hyderabad, Telangana State, is focused on developing and manufacturing high-quality, affordable medications, including multiple insulin analog biosimilars. GeneSys currently employs about 250 personnel and anticipates adding approximately 300 jobs for its new facility.

GeneSys has partnered Civica Rx, a U.S. non-profit generic drug company, to manufacture and distribute affordable insulin. Civica is dedicated to ensuring that essential medications are accessible and affordable for all patients.